The ongoing Covid-19 pandemic has yielded an unexpected advancement in the pharmaceutical industry with the approval of the first mRNA vaccines, which GlobalData expects will soon impact other indications.
This historical landmark could have significant implications, primarily in the oncology market since mRNA vaccines were being exclusively investigated in infectious and oncology diseases prior to the pandemic. Historically, mRNA vaccines were of interest in the oncology setting because multiple biomarkers could be targeted by this novel mechanism.
Given the current role of immunotherapies in oncology, mRNA vaccines pose a novel approach to trigger immune reactions against cancer cells. However, the novelty of mRNA vaccines has raised regulatory and manufacturing questions in addition to clinical limitations.
Covid-19 approvals showcase potential of mRNA vaccines
The recent approvals of Pfizer / BioNTech’s and Moderna’s mRNA vaccines in healthy patients, complemented by the historically unmatched magnitude to reach healthy patients worldwide, has helped surpass many barriers for mRNA vaccines while highlighting this novel mechanism of action. GlobalData expects this will propagate a new epicenter of interest in pursuing this drug class in oncology.
Currently, there are 44 ongoing clinical trials exploring mRNA vaccines, of which 23 are investigating infectious diseases. This includes Covid-19, which accounts for 60% of those clinical trials. Interestingly, only four out of the 44 clinical trials have made it to Phase III as a result of the sudden and immense demand to prevent the spread of Covid-19.
From an oncology viewpoint, the current pandemic will still serve to provide essential real-world data about the tolerability and effects of mRNA vaccines, since despite their approval and initial vaccination rollout, the long-term efficacy and side effects are still to be understood. As more data are gathered on these vaccines, GlobalData expects an increasing interest in bringing them into the oncology sector.
Key opinion leaders (KOLs) interviewed by GlobalData have repeatedly shown interest in novel mechanisms of action, particularly in immunotherapy. Prior to the pandemic, mRNA vaccines were one of many promising drug classes that were being explored equally with each other, with no expectation about which would be the next to impact the market. However, the sudden rise of mRNA vaccines makes it a prime candidate since there is a current spotlight on this drug class.
A supporting argument for the interest in mRNA vaccines is that out of the 21 ongoing non-infectious disease clinical trials that are exploring mRNA vaccines, all are being developed for oncology indications. Of these 21 trials, only seven are in Phase II, which demonstrates the relatively early stage of mRNA vaccines in oncology. Interestingly, the most represented company in these clinical trials is BioNTech, with seven of the 21 trials, followed by Roche/Genentech with three clinical trials and Moderna Inc with two clinical trials.
Image Credit: Shutterstock
Post by Amanda Scott, NA CEO. Follow her on twitter @tantriclens
Thanks to Heinz V. Hoenen. Follow him on twitter: @HeinzVHoenen
News
New, better coronavirus rapid test
Researchers at the Paul Scherrer Institute PSI and the University of Basel have developed a rapid test for COVID-19. Its novel functional principle promises reliable and quantifiable results concerning a patient's COVID-19 disease and [...]
Bio-Inspired Nanocoating Improves NIR and Biomedical Properties of Titanium Alloy
A group of researchers proposed an optimized electroforming strategy to achieve a bioinspired nano-holed TiO2 coated Ti6Al4V alloy, according to a study published in the journal ACS Applied Material Interfaces. Near-infrared (NIR) energy plays a critical part [...]
Seeking a hydrophilic nanoparticle solution to antibiotic resistance
The Centers for Disease Control and Prevention estimates that more than 2.8 million Americans experience antibiotic-resistant infections each year; more than 35,000 die from those infections. To address this critical and worldwide public health [...]
Nano-sized vesicles with ACE2 receptor could prevent, treat infection of SARS-CoV-2
Scientists at The University of Texas MD Anderson Cancer Center and Northwestern Medicine have identified natural extracellular vesicles containing the ACE2 protein (evACE2) in the blood of COVID-19 patients that can block infection from [...]
‘Superpower’ nano bubbles could treat, prevent current and future strains of SARS-CoV-2
Scientists at Northwestern Medicine and The University of Texas MD Anderson Cancer Center have identified natural nano-bubbles containing the ACE2 protein (evACE2) in the blood of COVID-19 patients and discovered these nano-sized particles can [...]
Groundbreaking AI Technology Diagnoses COVID-19 In Minutes
Pioneering Artificial Intelligence (AI) technology, developed by experts at University of the West of Scotland (UWS), is capable of accurately diagnosing Covid-19 in just a few minutes. The groundbreaking program is able to detect [...]
Antimicrobial resistance now a leading cause of death worldwide, study finds
Antimicrobial resistance poses a significant threat to humanity, health leaders have warned, as a study reveals it has become a leading cause of death worldwide and is killing about 3,500 people every day. More [...]
Evaluating Antiviral Activities of Nanoparticles Could Help Prevent Future Pandemics
The Necessity of Novel Antiviral Materials With the severe acute respiratory coronavirus 2 (SARS-CoV-2) being highly infectious and transmissible, the need for novel antiviral materials that can decrease viral activities has become paramount. Preparation procedures [...]
Nanocarrier therapy offers new hope for the treatment of Type 1 diabetes
Individuals living with Type 1 diabetes must carefully follow prescribed insulin regimens every day, receiving injections of the hormone via syringe, insulin pump or some other device. And without viable long-term treatments, this course [...]
Nanobubbles provide pathway to build better medical devices
Researchers from the University of Sydney Nano Institute and School of Chemistry have revealed that tiny gas bubbles – nanobubbles just 100 billionths of a metre high – form on surfaces in unexpected situations, [...]
Nanocomposite Hydrogel Improves Bone Repair Treatment
Innovative researchers have investigated the potential of incorporating a gelatin methacryloyl hydrogel functionalized with synthetic nanoclay laponite to improve the delivery of osteoblast derived extracellular vesicles for increased bone repair. This research has been [...]
Bioengineered nanoparticles show promise for fibrinogen manufacture
A couple of essential biomolecules play a key role in the process of blood clotting. One of these is a protein called fibrinogen. It is often given to those who have experienced heavy bleeding, [...]
Applying Nanoemulsions to the Food Sector
Nanoemulsions are a relatively new technology that has found significant use for delivering functional chemicals such as micronutrients, flavorings, bioactive molecules, and antimicrobial agents into food and beverage products. This article focuses on applying [...]
Researchers develop new method to increase effectiveness of nanomedicines
Researchers at Penn Medicine have discovered a new, more effective method of preventing the body's own proteins from treating nanomedicines like foreign invaders, by covering the nanoparticles with a coating to suppress the immune [...]
Researchers Create Nanobombs Capable of Attacking Only the Cancer Cells
Bioinspired by tunicates and mussels, a Korean research team has created a “bomb-like” anticancer therapeutic agent that only destroys cancer cells. Schematic diagram of the mechanism of action of photoactivatable adhesive nanobombs made with [...]
Long COVID could become Finland’s largest chronic disease, warns minister
(Reuters) - “Long COVID”, where symptoms of COVID-19 persist for months after an initial infection, could be emerging as a chronic disease in Finland, Minister of Family Affairs and Social Services Krista Kiuru said [...]
